Astellas and Theravance Report Additional Telavancin Data at 47th An... ( Results from Preclinical and Clini...)

Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC

Date:9/18/2007

Results from Preclinical and Clinical Studies Demonstrate Activity of

Investigational Agent against Gram-Positive Bacteria

CHICAGO, Sept. 18 /PRNewswire/ -- Astellas Pharma US, Inc. and Theravance, Inc. (Nasdaq: THRX) announced today results with the investigational compound telavancin from the largest subset of surgical-site-associated complicated skin and skin structure infections (cSSSIs) from a controlled Phase 3 clinical program in patients with complicated Gram-positive cSSSIs, and results from preclinical and surveillance studies were recently presented at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Chicago, Illinois.

Telavancin is a novel lipoglycopeptide injectable antibiotic discovered by Theravance that was engineered to have a unique, multifunctional mechanism of action; it inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane function. Telavancin is currently being evaluated by regulatory authorities in the United States and Europe for its safety and efficacy in the treatment of complicated skin and skin structure infections and is in Phase 3 studies for the treatment of hospital-acquired pneumonia.

The following clinical activity of telavancin was reported at ICAAC. New data from an analysis of a subset of nearly 200 patients with surgical-site-associated complicated skin and skin structure infections (cSSSIs) suggest that once-daily telavancin is clinically active in surgical-site-associated cSSSIs due to Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). These data are from the ATLAS (Assessment of TeLAvancin in complicated Skin and skin structure in
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
3. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
4. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. In Vivo Signal Transduction Pathway Reporting Systems
7. Improved Vectors for PathDetect Trans-Reporting Systems
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. Cis-Reporting System Monitors Intracellular Calcium Mobilization
10. Cis-Reporting System Monitors Intracellular Calcium Mobilization
11. PatchMan - Test Report

Post Your Comments:

Astellas and Theravance Report Additional Telavancin Data at 47th An...( Results from Preclinical and Clini...)